Skip to main content

Schedule 2017

With the biggest and best line up of conference speakers we have ever assembled the 2017 LDN Conference will, without doubt, be the best yet.

Below is the confirmed line up for all 3 days.

Exhibitors Opening Times

Friday and Saturday

8.30 Exhibitors Open | 6.30 Exhibitors Close

Sunday

8.30 Exhibitors Open | 2.30 Exhibitors Close

To view the bio of the speakers click on their picture or go to the speakers page.

9:00 - 9:05

Welcome

Linda Elsegood

9:05 - 9:10

Introduction

Dr. Mark Mandel

9:10 - 9:55

Using an Old Drug to Trick the Immune System into Healing Itself

Pharmacist Stephen Dickson

Covering the historical uses, background, and complex issues surrounding Naltrexone. A more in-depth review and discussion of evidence published in The LDN Book. This lecture gives a background to health professionals in the complex interacting biological pathways involved in using Naltrexone in autoimmune diseases and cancer.

9:50 - 10:25

New Cost-Effective Treatment for Autoimmune Illnesses, Cancer, and Chronic Diseases?

Dr. John Kim

Today LDN therapy has gained traction in many arenas. Conventional pharmaceuticals are utilizing LDN combined with medications. Integrative/functional medicine practices are beginning to embrace LDN therapy. The interest in LDN is growing in people who are suffering from autoimmune conditions, cancer, and other chronic diseases. LDN offers many advantages including cost-effectiveness. Today, LDN therapy can be administered for less than a dollar per day in the U.D. through compounding pharmacies. Therefore, the potential cost-saving of LDN therapy for many conditions are enormous. This presentation will focus on the role of LDN as a novel anti-inflammatory agent for the central nervous system, the role of LDN for treating endorphin deficiency syndromes, LDN as immuno-adaptogen, and atypical uses of LDN therapy.

10:25 - 10:45

Morning Break

A short 20 minute break

10:45 - 11:30

The Role of the Opioid System in Immune-Mediated Disease

Dr. Anthony Turel

The purpose of this presentation is to provide a scientific explanation regarding the various receptors in the opioid system and their potential role in modulating the effects of immune disorders. The biological effect of the opioid receptor antagonist naltrexone will be explained, and its unique properties discussed.

11:45 - 12:45

Q&A

The Q&A Panel

12:45 - 13:45

Lunch

A one hour break for lunch

1:45 - 2:00

Modern laboratory tests for diagnosing Lyme disease

Dr Armin Schwarzbach

Lyme disease is like a ‘chameleon’ of symptoms and laboratory tests. Chronic multiple symptoms of Lyme disease can include: chronic fatigue, joint and muscle pain, neck-pain, neurological symptoms like burning hands/feet or sensitivity problems, sleeplessness, short-term memory loss, concentration problems, psychiatric problems like aggressiveness or anxiety, autoimmune disorders. Chronic Lyme disease can be attributed to so-called unexplained syndromes like Chronic Fatigue Syndrome, Myalgic Encephalitis, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Alzheimer’s, Parkinsonism, Rheumatoid Arthritis, Sjögren's Syndrome, Hashimoto thyroiditis, tinnitus, depression, schizophrenia, Carpal Tunnel Syndrome, Autism.

There is a lack of confidence in falsely established laboratory tests for antibodies like the Borrelia-ELISA test or Borrelia Westernblots, which are not standardized and very often false-negative. Doctors need the practical help by better and improved laboratory tests, such the SeraSpot (modern Borrelia Westernblot), EliSpot (modern T-cell test) and CD57-cells. The modern microarray SeraSpot offers a better standardization in comparison with normal Westernblot tests, shows an improved sensitivity by using the new MicroArray analytics and covers all 3 main Borrelia subspecies (Borrelia sensu stricto, Borrelia garinii and Borrelia afzelii) by combining recombinant and native Borrelia antigens. The Elispot reflects the current activity of Borrelia burgdorferi and covers all 3 main Borrelia subspecies by combining recombinant and native Borrelia antigens. The CD57-cells reflect the chronic activity of Borrelia burgdorferi and show in newer studies correlations with Autism too. The presentation will describe all modern analytical laboratory test possibilities: SeraSpot, EliSpot and CD57-cells. 

2:00 - 2:45

Immune Dysfunction and Chronic Lyme Disease

Dr. Kent Holthorf

Chronic Lyme disease is the fastest growing vector-borne illness in the country, with more cases diagnosed per year than HIV and breast cancer combined. However, because diagnosing Lyme can be difficult, many people who actually have Lyme may be misdiagnosed with other conditions such as chronic fatigue syndrome, fibromyalgia, lupus, multiple sclerosis, mixed connective tissue disease, depression, bipolar depression, seizure disorder, ALS, Alzheimer's IBS, and rheumatoid arthritis. Many experts believe the true number of cases is much higher. A hallmark of chronic Lyme disease is an underlying immune dysfunction that not only limits the ability to accurately diagnose Lyme, leaving many such patients misdiagnosed, but also serves as a major reason for lack of treatment response to antibiotics with an inability to eradicate the chronic infection.

The Borrelia bacteria (cause of Lyme disease) transforms from an acute to a chronic infection by transforming the body to a TH2 "extracellular" dominant response and then converting from a free swimming spirochete form in the blood into an intracellular form (L-form) to escape the elevated TH2 immunity. The suppressed and down-regulated TH1 intracellular immune response becomes an ineffective immune response by the body and an effective evasion strategy, which is the hallmark of transformation to late-stage Lyme dissemination. While there are many controversies surrounding the diagnosis of chronic Lyme disease, identification of this immune dysfunction that is consistently found in this illness can greatly aid in the diagnosis of tick-borne illness and to identify the stage and even severity of Lyme disease. The level of immune dysfunction may also be the single most important determinant of treatment success. Thus, appropriate immune modulating therapies that are able to restore normal functioning immunity may be the biggest necessary leap forward in the development of an effective treatment protocol for this multi-system illness.

2:45 - 3:00

A Novel Approach to Type 1 Diabetes Mellitus

Paul Battle

Description:  P.A. Battle will present a case where a 10-year-old girl with Diabetes type 1 was not controlled with an insulin pump and strict diet. After LDN was introduced into her regimen, her diabetes was controlled, with less insulin requirements.

3:00 - 3:20

Afternoon Break

A short 20 minute break

3:20 3:50

Children are not Small Adults: Considerations for Medication Dosing and Delivery

Dr. Deanna Windham

The session explores dosing and delivery recommendations for children on less common medications.

3:50 - 4:05

Psoriasis: A Novel Approach to Treatment

Dr. Deanna Windham

Explores the science behind the newest modalities of treatment for psoriasis with case studies and recommendations.

4:05 - 4:20

Navigating the Narrative with your Health Care Team

Dr. Nasha Winters

This discussion offers insight on how to articulate the need and application of LDN respectfully and thoughtfully with your health care team in order to create a common language in the medical system, and the ability to receive access to this powerful medicine.

4:20 - 5:20

Q&A

The Q&A Panel

9:00 9:05

Welcome

Linda Elsegood

9:05 - 9:10

Introduction

Dr. Mark Mandel

9:10 10:10

Approach to Managing Chronic Pain

Dr. Pradeep Chopra

Understanding the mechanism of chronic pain with a focus on neuropathic pain. The presentation will discuss the mechanism of autoimmune mediated chronic pain and treatment strategies.

10:10 - 10:30

Morning Break

A short 20 minute break

10:30 - 11:00

The Ten Most Important Fibromyalgia Discoveries of 2016 and 2017

Dr. Jarred Younger

Research into fibromyalgia has increased dramatically in the past few years, with 50 new studies being published every month. Fibromyalgia now attracts the interest of researchers across many scientific disciplines, increasing the chances that we can make substantial progress in the near future. We will discuss the ten most significant scientific reports in fibromyalgia over 2016 and 2017, covering studies in fields such as clinical trials, immunology, neuroimaging, genetics, endocrinology, psychology, and epidemiology. The discussed studies will represent the most important advances in fibromyalgia diagnosis and treatment. We will conclude with a description of the next steps in fibromyalgia research, and what we can expect in the next few years.

11:00 - 11:15

Turning Down the Volume on Fibromyalgia Pain

Dr. Ginevra Liptan

Fibromyalgia is a common condition of widespread pain reflecting central nervous system sensitization. Fibromyalgia pain is notoriously resistant to standard treatments, in part because they do not address the key contribution of the glial cells, the support and immune cells that surround neurons. Central sensitization is a complex process resulting in abnormal glial cell activation and inflammation.

Low Dose Naltrexone (LDN) calms activated glial cells and lowers the volume of pain transmitted to the brain. Stanford University researchers found in two separate studies that LDN substantially reduced fibromyalgia pain. Clinical experience supports these research findings, and the presentation will briefly review two eyars of data from the use of LDN in a fibromyalgia specialty practice.

11:15 - 11:30

Physiology and Treatment of Postcoital Dysphoria

Dr. Mark Shukhman

Changes in mood following sexual intercourse or other sexual experiences is a well-described phenomenon, which is surprisingly common. Most of the time, it is not recognized as a physiological consequence, because of the tendency to explain it with psychological or psycho-social reasons. In fact, in addition to the psychology of the phenomenon, the role of dopamine and endorphins, along with the multitude of other neurotransmitters, is hypothesized in the literature. This presentation will focus on Low Dose Naltrexone, an opioid receptors modulator, as a remedy to lessen the effect.

11:30 - 12:15

Q&A

The Q&A Panel

12:15 - 1:15

Lunch

A one hour break for lunch

1:15 - 2:15

Irritable Bowel Syndrome: The Roles of Small Intestinal Bacterial Overgrowth (SIBO) and Mucosal/Systemic Inflammation

Dr. Leonard Weinstock

In the last 16 years there is a shift in the paradigm of understanding the pathophysiology and treatment of irritable bowel syndrome (IBS). Two key factors in the pathophysiology are small intestinal bacterial overgrowth and mucosal/systemic inflammation. A significant portion of irritable bowel syndrome is due to SIBO and dysbiosis. The nature of the gases produced by bacterial fermentation change the presentation of the bowel symptoms. The underlying cause of post-infectious IBS and the application to IBS in general is a major development–-autoimmune IBS is a newly recognized condition that takes the S out of IBS and makes us able to call it a disease.

2:15 - :30

Crohn's Disease: Latest Integrative Immunologic Therapies

Paul S. Anderson, NMD

Crohn's Disease is an incredibly common autoimmune digestive system condition which has limited treatment options in standard medicine. For the last three decades, Dr. Anderson has treated patients with Crohn's Disease in an integrative setting with greatly improved outcomes in most cases. In this session, he will share the outline of his integrated care and the latest cutting edge additions to these therapies.

2:30 - 2:45

Fire in the Hole--Intestinal Permeability, The Development of Autoimmune Disease, and a Comprehensive Approach to Healing the Gut

Dr. Tom O'Bryan

Autoimmune diseases are a primary cause of morbidity and mortality in the industrialized world. That means it's in our offices every day. The number of people diagnosed with an autoimmune disease is increasing exponentially in our country. Estimates are that anywhere from three to seven out of every ten new patients coming into your office are suffering from an autoimmune mechanism (whether it has been recognized and diagnosed or not). The volume of information now of the underlying mechanisms that set the stage and contribute to the development of autoimmune disease is overwhelming.

Without recognizing and addressing the underlying mechanisms triggering the presenting complaints, the Practitioner may be proverbially 'chasing the tail' of the pathology with temporary symptom relief. The Practitioner who has a deep understanding as to when to suspect an immune reaction to an environmental trigger, has access to thorough testing tools, and who also understands and supplies comprehensive treatment protocols, that Practitioner will see results in their Practice like never before. This Presentation will outline the Trilogy in the development of autoimmune disease and its musculoskeletal/neurological presentations with a deep emphasis on testing and treatment protocols that have consistently demonstrated dramatic results.

2:45 - 3:00

What the Bleep Can I Eat?! Making Sense of Conflicting Autoimmune Diets

Jill Brook, M.A.

This short presentation will introduce several different nutritional approaches to managing autoimmune disorders, and explain how each plan takes a different approach:

  • Anti-inflammatory basics
  • Paleo Autoimmune Protocol
  • Low FODMAP
  • Low Histamine
  • Low Sulpher
  • Specific Carbohydrate Diet 

LDN dietary tips It will give a quick explanation of which conditions may benefit most from each nutrition plan.

3:00 - 3:20

Afternoon Break

A short 20 minute break

3:20 - 3:50

The Role of Non-Cytotoxic Drugs in the Management of Cancer

Professor Angus Dalgleish

It is becoming clear that drugs other than cytotoxic chemotherapy agents have a major impact on certain cancer types. Our team has researched a number of these agents, how they can be useful alone and in combination with other drugs and other modalities. These include the Artemisinins, and we are particularly focused on Artusenate, which is in small clinical trials in colorectal cancer.  Another group of drugs that appear to be effective in certain cancer types are based on the Cannabinoids. Our own group has shown that these can have marked inhibition of cell lines, without being cytotoxic, but more importantly, on withdrawal of the drug, the cell lines become much more susceptible to cell death and being killed by other modalities. Our group has shown that cannabinoids, in certain mixtures, can greatly enhance the sensitivity of murine gliomas to radiotherapy and this has obvious clinical translation possibilities.

Another agent that can have similar cytostatic properties and effect on the immune response without having direct anti-cancer effect is Naltrexone, where the effect is more evident at lower doses. We have shown that in addition to using a different group of receptors other than the opiates (certain Toll-like receptors) it also has a markedly different effect on gene expression, whether the low or high dose or normal therapeutic dose is used.

These and other drugs that affect inflammation and metabolism, such as a variety of anti-inflammatory agents, which include Aspirin and statins, as well as metabolic agents such as Metformin, in addition to several other widely used agents that have marked anti-cancer activity in their own right, such as Doxycycline and anthelmintic treatment, may make all the difference in enhancing outcome when added into, supplementing, other treatments.

3:50 - 4:20

Broad spectrum, Gentler Anti-Neoplastics: Breaking the cycle of toxic therapy

Dr Akbar Khan

This presentation will cover the use of re-purposed drugs that have broad spectrum anti-cancer activity through various mechanisms, and are also non-toxic unlike conventional chemotherapy. Various therapies will be reviewed, with an emphasis on oral low dose naltrexone (other therapies include dichloroacetate and dimethylsulfoxide).

4:20 - 5:20

Q&A

The Q&A Panel

9:00 - 9:05

Welcome

Linda Elsegood

9:05 - 9:10

Introduction

Dr. Mark Mandel

9:10 9:25

Thyroid Autoimmunity: Causal Relationships & Novel Therapeutics

Dr. John A. Robinson

It is well known that autoimmunity is the leading cause of thyroid dysfunction in the developed Western world. The goal of any comprehensive thyroid treatment approach should consider the step before the autoimmunity leading to a Tolle Causum, or Treat the Cause, approach to the philosophical and intellectual approach of the physician. In addition, both novel and traditional approaches to thyroid disease management exist that offer an often highly advantageous and superior treatment alternative. This lecture will present clinical evidence of patient improvement and health optimization in respect to thyroid function and metabolism while undergoing a comprehensive treatment that treats the cause. The clinical evidence of improvement/non-improvement will be reported through the measurement of various markers including serum thyroid autoantibodies including anti-thyroidperoxidase (anti-TPO), anti-thyroglobulin (anti-TG), CRP (C- Reactive Protein), RBC sedimentation rate, serum IgG (Immunoglobulin G) reactions to ingested foods, brachioradialis reflex speed, resting metabolic rate as measured by indirect calorimetry, and patient self-reporting of symptoms, among other measurements.

9:25 9:40

Vitamin D and Autoimmune Disease: A Systematic Review of the Literature

Jill Cottell, MD

Vitamin D deficiency has been shown to be a risk factor for a number of medical illnesses, including autoimmune disease. Because of this link, many practitioners routinely recommend vitamin D supplementation to their patients. Is there really any evidence to support this practice, and what are the benefits and risks associated with vitamin D treatment? We will examine the evidence in a systematic review of the literature.

9:40 - 10:10

Treating the Zebras in Primary Care

Jill Cottell, MD

Across the globe, autoimmune disease is on the rise at an alarming rate.  Patients are facing treatment options that are expensive and fraught with many potential side effects.  Many of them are learning about low dose naltrexone for the first time, and they are coming to their primary care provider with questions.  We need to be able to answer these questions and provide them with the care they deserve.

10:10 - 10:40

Review of Recent Statistics for Patients Taking LDN in a Special Needs Pediatric Practice

Dr. Brian Udell

This session will review factors affecting the success of LDN as a treatment including: accurate diagnosis, choosing candidates most likely to succeed, addressing gut and metabolic issues first, and addressing other co-morbidities as they exist or arise.

11:00 - 11:30

Opioid Antagonists and Traumatic Brain Injury

Ulrich Lanius, Ph.D. and Galyn Forster, MS, LPC

Review of recent research and controversies regarding the use of opioid antagonists as treatment interventions for the effects of Traumatic Brain Injury (TBI/MTBI). A number of case studies are presented and timing of interventions and preliminary dosing strategies are discussed. It is suggested that opioid antagonists may potentially be an effective intervention for the effects of TBI/MTBI.

11:30 - 11:45

A Medication to Gain Self-Awareness: Treatment of Dissociative Symptoms in Trauma-Related Disorders

Dr. Wiebke Pape

Dissociative symptoms (like derealisation, emotional numbing, 'losing time,' the lack of self-awareness) occur in most of the cases of trauma-related disorders. Psychotherapeutic treatment is difficult and slow-moving, and there is hardly any pharmacologic strategy that is recommended.

Following the hypothesis that blocking opioid receptors leads to a decline in opiate modulated dissociative phenomena, since 1999 experiences with naltrexone as medication for dissociative symptoms have been gained (mainly in a dose of 25 to 100 mg/d). In this presentation, first experiences with LDN (2-6 mg/d) in the treatment of patients with severe trauma-related and dissociative disorders will be described.

The low dose treatment with naltrexone proved to be effective: 11 out of 15 patients reported immediate positive effects, 7 described a lasting helpful effect. The majority of patients who felt positive effects reported a clearer perception of both their surroundings as well as of their inner life. Assessment of reality and dealing with it improved, as did the perception of their own body and affects as well as self-regulation. The treatment was very low in side effects.

Treatment with low dose naltrexone may be a helpful element in the treatment of patients with complex posttraumatic stress disorder. However, it has to be realized that the decrease of dissociation may lead patients to a not yet resolvable challenge, in as much as dissociation had previously been a necessary mechanism of self-protection.

11:45 - Noon

A Guide to Testing Steroid and Peptide Hormones in Different Body Fluids

Dr. David T. Zava

Hormone therapy is a mainstay in treatment of hormonal imbalances and helps guide and optimize the type, dosage, and delivery of the hormone. Hormone therapy without first testing hormone levels can lead to less than optimal therapy.

Hormone testing for steroid hormones is most commonly performed using venipuncture serum or plasma and urine.  Other body fluids (saliva and fingertip capillary dried blood spots-DBS) are becoming more commonplace due to convenience of collection and more accurate assessment of bioavailable hormone levels.

In this lecture I will discuss the pros and cons of using different body fluids and methods (EIA vs LC-MS/MS) for testing steroid hormones, produced endogenously or taken exogenously by different routes of administration (oral, topical, troche, sc pellets, etc.).  I will explain why most body fluids are appropriate for hormone testing following exogenous hormone supplementation but that serum and urine are less optimal than saliva and capillary blood for detecting hormones following topical hormone delivery. 

Noon - 12:15

LDN and Pets

Dr. Mark Mandel

12:15 - 1:15

Q&A

The Q&A Panel

1:15 1:25

Summary

Dr. Mark Mandel